Oculis Holding Net Income Over Time
| OCS Stock | 28.68 0.21 0.73% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Oculis Holding Performance and Oculis Holding Correlation. Is there potential for Biotechnology market expansion? Will Oculis introduce new products? Factors like these will boost the valuation of Oculis Holding. Anticipated expansion of Oculis directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Oculis Holding listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.78) | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets | Return On Equity |
Understanding Oculis Holding AG requires distinguishing between market price and book value, where the latter reflects Oculis's accounting equity. The concept of intrinsic value - what Oculis Holding's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Oculis Holding's price substantially above or below its fundamental value.
It's important to distinguish between Oculis Holding's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oculis Holding should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Oculis Holding's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Oculis Holding AG and related stocks such as Xencor Inc, Kodiak Sciences, and AnaptysBio Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XNCR | (11.2 M) | (11.2 M) | (8.6 M) | (60.3 M) | (16.4 M) | (17.6 M) | 23.6 M | (48.9 M) | (70.4 M) | 26.9 M | (63.5 M) | 82.6 M | (55.2 M) | (126.1 M) | (232.6 M) | (209.4 M) | (198.9 M) |
| KOD | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (27.9 M) | (41.4 M) | (47.4 M) | (133.1 M) | (267 M) | (333.8 M) | (260.5 M) | (176.2 M) | (158.6 M) | (166.5 M) |
| ANAB | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | 232 K | (5.4 M) | (4.3 M) | (30.1 M) | (61.7 M) | (97.3 M) | (19.9 M) | (57.8 M) | (128.7 M) | (163.6 M) | (145.2 M) | (130.7 M) | (124.2 M) |
| URGN | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (4.6 M) | (12.7 M) | (1.9 M) | (20 M) | (75.7 M) | (105.1 M) | (128.5 M) | (110.8 M) | (109.8 M) | (102.2 M) | (126.9 M) | (114.2 M) | (108.5 M) |
| PHAT | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (209.7 M) | (129.1 M) | (143.9 M) | (197.7 M) | (201.6 M) | (334.3 M) | (300.9 M) | (285.8 M) |
| NRIX | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (21.7 M) | (43.2 M) | (117.2 M) | (166 M) | (143.9 M) | (193.6 M) | (264.5 M) | (238 M) | (226.1 M) |
| NKTR | (5.3 M) | (134 M) | (171.9 M) | (162 M) | (53.9 M) | (81.2 M) | (153.5 M) | (96.7 M) | 681.3 M | (440.7 M) | (444.4 M) | (523.8 M) | (368.2 M) | (276.1 M) | (119 M) | (107.1 M) | (112.4 M) |
| SANA | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (130.8 M) | (278.6 M) | (344.2 M) | (266.4 M) | (283.3 M) | (266.8 M) | (240.1 M) | (252.1 M) |
| BBOT | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (3.5 K) | (64.7 M) | (74.3 M) | (66.8 M) | (63.5 M) |
Oculis Holding AG and related stocks such as Xencor Inc, Kodiak Sciences, and AnaptysBio Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Oculis Holding AG financial statement analysis. It represents the amount of money remaining after all of Oculis Holding AG operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Oculis Holding AG | OCS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Bahnhofstrasse 20, Zug, |
| Exchange | NASDAQ Exchange |
null 28.68
Additional Tools for Oculis Stock Analysis
When running Oculis Holding's price analysis, check to measure Oculis Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oculis Holding is operating at the current time. Most of Oculis Holding's value examination focuses on studying past and present price action to predict the probability of Oculis Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oculis Holding's price. Additionally, you may evaluate how the addition of Oculis Holding to your portfolios can decrease your overall portfolio volatility.